JPX · 4519.T
Chugai Pharmaceutical Co., Ltd.
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
Loading market information…
JPX · 8086.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Nipro Corporation’s quoted price sits in the lower half of its reported 52-week range, 22.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Nipro Corporation’s forward annual dividend is ¥24 per share, paid semi-annual. The forward yield is 1.76% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Nipro Corporation’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of ¥21. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nipro Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:34 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2024 | May 12, 2025 | -¥9-117.58% vs estimate | ¥165.3B+6.95% vs estimate |
|---|
| Q3 2024 | Feb 7, 2025 | ¥40+51.01% vs estimate | ¥167.27B+2.02% vs estimate |
|---|
| Q2 2024 | Nov 8, 2024 | -¥15-165.95% vs estimate | ¥159.63B-0.86% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥6,822+¥169 (+2.54%)
Chugai Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.24% below the high.
¥6,651+¥180 (+2.78%)
Takeda Pharmaceutical Company Limited’s quoted price sits in the upper half of its reported 52-week range, 0.91% below the high.
¥2,405+¥36 (+1.5%)
Terumo Corporation’s quoted price sits in the upper half of its reported 52-week range, 10.58% below the high.
¥1,742-¥27 (-1.53%)
Olympus Corporation’s quoted price sits in the lower half of its reported 52-week range, 21.19% below the high.
¥1,617+¥32 (+1.99%)
Nihon Kohden Corporation’s quoted price sits in the upper half of its reported 52-week range, 14.27% below the high.
¥1,421+¥9 (+0.64%)
Nakanishi Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.04% below the high.
¥1,513+¥17 (+1.14%)
Mani, Inc.’s quoted price sits in the lower half of its reported 52-week range, 22.61% below the high.
¥1,843+¥8 (+0.44%)
Menicon Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 11.65% below the high.
